Regulatory framework and challenges for live biotherapeutic products in Taiwan
Journal of Food and Drug Analysis · 13.06.2025 · 33 (2) · 97-105
DOI: 10.38212/2224-6614.3540 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Food and Drug Analysis, online erschienen am 13.06.2025. Verfasst von Shirley Pan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Taiwan Food and Drug Administration, Ministry of Health and Welfare, Taipei, Taiwan. Hauptthemen laut MEDLINE: Biological Products. Die Arbeit wurde bisher 29-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Products containing live microorganisms may be classified as food or drugs depending on their intended use; live biotherapeutic products (LBPs) with therapeutic claims are defined as medicinal products containing live bacteria or yeasts intended to prevent or treat disease. Based on their characteristics, LBPs are classified as biological drugs and must be registered as biological drugs before they can enter the Taiwanese market. As research into the microbiota and its role in health and disease continues to advance, LBPs are expected to play an increasingly important role in medicine and biotechnology. With the growing popularity of microbial applications in recent years, there is still a lack of awareness regarding the management and regulation of such products. This article outlines the development, manufacturing, and marketing requirements of LBPs in Taiwan. After searching relevant literature, we summarized the regulations or related guidelines on LBPs from regulatory agencies such as the U.S. FDA, EMA, PMDA, and ICH. And compare the current requirements for LBPs in Taiwan. Key regulatory aspects of LBPs in Taiwan include definitions and classifications, quality and manufacturing requirements, clinical evidence, labeling and packaging information, post-marketing surveillance, etc. Regulations of LBPs in Taiwan align with international standards, but Taiwan authorities must be more inclusive in addressing new challenges facing LBPs innovation. This highlights the importance of continuous regulatory adaptation to foster innovation while ensuring safety and efficacy. Collaboration between regulatory bodies, industry stakeholders, and scientific communities will be essential to promoting innovation while maintaining robust regulatory oversight in the LBPs sector. In summary, while LBPs have significant therapeutic potential, addressing the regulatory challenges associated with their development, approval, and post-marketing surveillance is critical to ensure their safety, efficacy, and successful integration into clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Taiwan Food and Drug Administration, Ministry of Health and Welfare, Taipei, Taiwan.
Zitieren
APA
Pan, S., Hsu, J. C., Hung, K. T., & Ho, C. J. (2025). Regulatory framework and challenges for live biotherapeutic products in Taiwan. Journal of Food and Drug Analysis, 33(2), 97-105. https://doi.org/10.38212/2224-6614.3540
Vancouver
Pan S, Hsu JC, Hung KT, Ho CJ. Regulatory framework and challenges for live biotherapeutic products in Taiwan. Journal of Food and Drug Analysis. 2025;33(2):97-105. doi:10.38212/2224-6614.3540
BibTeX
@article{Pan2025,
author = {Pan, Shirley and Hsu, Jia-Chuan and Hung, Kuo-Teng and Ho, Ching-Jung},
title = {Regulatory framework and challenges for live biotherapeutic products in Taiwan},
journal = {Journal of Food and Drug Analysis},
year = {2025},
volume = {33},
number = {2},
pages = {97--105},
doi = {10.38212/2224-6614.3540}
}
EUVIMED